NOTCH1 signaling in head and neck squamous cell carcinoma
Biomarker-driven targeted therapies are lacking for head and neck squamous cell
carcinoma (HNSCC), which is common and lethal. Efforts to develop such therapies are …
carcinoma (HNSCC), which is common and lethal. Efforts to develop such therapies are …
MicroRNA-143 suppresses oral squamous cell carcinoma cell growth, invasion and glucose metabolism through targeting hexokinase 2
X Sun, L Zhang - Bioscience Reports, 2017 - portlandpress.com
miRNAs are non-coding RNAs that have functions to regulate gene expression and play
essential roles in a variety of biological processes of cancers. In the present study, we report …
essential roles in a variety of biological processes of cancers. In the present study, we report …
[HTML][HTML] ENO1 silencing impaires hypoxia-induced gemcitabine chemoresistance associated with redox modulation in pancreatic cancer cells
L Wang, R Bi, H Yin, H Liu, L Li - American Journal of Translational …, 2019 - ncbi.nlm.nih.gov
Resistance to Gemcitabine (GEM) is a crucial problem in treatment of pancreatic cancer.
Many studies indicate the direct impact of glycolytic enzyme on chemoresistance. However …
Many studies indicate the direct impact of glycolytic enzyme on chemoresistance. However …
Inhibitors of the protein–protein interaction between phosphorylated p62 and Keap1 attenuate chemoresistance in a human hepatocellular carcinoma cell line
D Yasuda, T Ohe, K Takahashi, R Imamura… - Free Radical …, 2020 - Taylor & Francis
Resistance to anticancer agents has been an obstacle to develo** therapeutics and
reducing medical costs. Whereas sorafenib is used for the treatment of human …
reducing medical costs. Whereas sorafenib is used for the treatment of human …
Artesunate and cisplatin synergistically inhibit HNSCC cell growth and promote apoptosis with artesunate‑induced decreases in Rb and phosphorylated Rb levels
H Okamoto, K Yoshikawa, A Shimada… - Oncology …, 2023 - spandidos-publications.com
In the treatment of head and neck cancer, cisplatin is often used as a therapeutic agent;
however, its efficacy is limited and it can cause renal dysfunction as an adverse effect. For …
however, its efficacy is limited and it can cause renal dysfunction as an adverse effect. For …
Enolase 1 correlated with cancer progression and immune-infiltrating in multiple cancer types: a pan-cancer analysis
W Xu, W Yang, C Wu, X Ma, H Li, J Zheng - Frontiers in Oncology, 2021 - frontiersin.org
Enolase 1 (ENO1) is an oxidative stress protein expressed in endothelial cells. This study
aimed to investigate the correlation of ENO1 with prognosis, tumor stage, and levels of tumor …
aimed to investigate the correlation of ENO1 with prognosis, tumor stage, and levels of tumor …
Sensitivity to cisplatin in head and neck cancer cells is significantly affected by patient-derived cancer-associated fibroblasts
B Peltanova, M Liskova, J Gumulec… - International Journal of …, 2021 - mdpi.com
Cancer-associated fibroblasts (CAFs) are one of the most abundant and critical components
of the tumor stroma. CAFs can impact many important steps of cancerogenesis and may also …
of the tumor stroma. CAFs can impact many important steps of cancerogenesis and may also …
Granulin A synergizes with cisplatin to inhibit the growth of human hepatocellular carcinoma
Cisplatin is one of the most potent chemotherapy drugs widely used for cancer treatment.
However, due to resistance and toxicity, the application of cisplatin for the treatment of …
However, due to resistance and toxicity, the application of cisplatin for the treatment of …
Current understanding of the potential of proteomics and metabolomics approaches in cancer chemoresistance: A focus on multiple myeloma
V Chanukuppa, R Taware, T Chatterjee… - Current Topics in …, 2018 - ingentaconnect.com
Chemoresistance is one of the major hurdles in cancer treatment leading to recurrence of
cancer and affects the overall survival of patients. Cancer chemoresistance can be …
cancer and affects the overall survival of patients. Cancer chemoresistance can be …
Comparative proteomic analysis of advanced ovarian cancer tissue to identify potential biomarkers of responders and nonresponders to first-line chemotherapy of …
Conventional treatment for advanced ovarian cancer is an initial debulking surgery followed
by chemotherapy combination of carboplatin and paclitaxel. Despite initial high response …
by chemotherapy combination of carboplatin and paclitaxel. Despite initial high response …